Three 100-mg vials of alteplase injection a were reconstituted with sterile water b to yield solutions of 0.5, 1, and 2 mg/mL. A transfer adapter c was used to draw 1-mL samples into 5- mL plastic ...

Intravenous alteplase (recombinant tissue plasminogen activator) is restricted for use within 3 h from stroke onset by marketing authorizations. Some patients are treated beyond this approved time ...

The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

Unlike alteplase, tenecteplase is delivered with a single, seconds-long injection, considerably speeding treatment time. Dr.

Alteplase is delivered with a rapid initial dose followed by a slow-drip infusion over the next hour, researchers said. This is a complicated process that can cause interruptions or delays in ...

Alteplase was approved in 1996 to help treat ... By comparison, tenecteplase is delivered with a single, seconds-long injection, researchers said. The new drug was approved for use in stroke ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...